Seeking Alpha

More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at...

More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs